Dr. Ruby A. Deveras, MD
Hematology & Oncology (Hematology & Oncology Physician)
303 N Clyde Morris Blvd, Halifax Regional Oncology Center
Daytona Beach, FL 32114
- Medicare participating
At a glance
- Medical school
- State University of New York at Stony Brook, School of Medicine (1996)
- Years since graduation
- 30
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 309
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1996Medical school: State University of New York at Stony Brook, School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
FL license ME75526
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Adventhealth Daytona Beach Daytona Beach, FL
- Adventhealth PAlm Coast Palm Coast, FL
- Halifax Health Medical Center Daytona Beach, FL
- Adventhealth New Smyrna Beach New Smyrna Beach, FL
- Halifax Health /uf Health Medical Center of Delton Deltona, FL
Medical groups
- Halifax Healthcare Systems Inc (356 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 309
- Services billed
- 681
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 283 | 187 |
| Established patient office or other outpatient visit, 40-54 minutes | 208 | 83 |
| Established patient office or other outpatient visit, 20-29 minutes | 129 | 116 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 66 | 33 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 48 | 25 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 37 | 34 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 30 | 28 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | 21 | 19 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Daytona Beach, FL | 265 |
| Eliquis (apixaban) Other prescribers in Daytona Beach, FL | 83 |
| Lorazepam Other prescribers in Daytona Beach, FL | 69 |
| Tamoxifen Citrate Other prescribers in Daytona Beach, FL | 40 |
| Ondansetron Hcl Other prescribers in Daytona Beach, FL | 39 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Daytona Beach, FL | 39 |
| Oxycodone Hcl Other prescribers in Daytona Beach, FL | 39 |
| Exemestane | 36 |
| Letrozole Other prescribers in Daytona Beach, FL | 29 |
| Gabapentin Other prescribers in Daytona Beach, FL | 27 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 24 companies reported 78 payments worth $2,324 in total to this clinician.
| Penumbra, Inc. | $303 |
|---|---|
| Daiichi Sankyo Inc. | $217 |
| E.r. Squibb & Sons, L.l.c. | $213 |
| Janssen Biotech, Inc. | $204 |
| AstraZeneca Pharmaceuticals LP | $204 |
| Caris Mpi, Inc. | $182 |
| Astellas Pharma US Inc | $157 |
| Adc Therapeutics America, Inc. | $99.35 |
| Food and Beverage | $2,324 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $1,750 in research payments for these studies, mostly to the institutions running them.
- Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry. The purpose of the Connect Myeloid disease registry is to provide unique insights into treatm…
Celgene Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.